181 related articles for article (PubMed ID: 17083555)
1. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Siqueira RC; Costa RA; Scott IU; Cintra LP; Jorge R
Acta Ophthalmol Scand; 2006 Dec; 84(6):834-5. PubMed ID: 17083555
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
3. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
4. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
Kumar A; Sinha S
Can J Ophthalmol; 2007 Apr; 42(2):335-6. PubMed ID: 17392871
[No Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
7. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2006 Oct; 84(5):707-8. PubMed ID: 16965507
[No Abstract] [Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization.
Arriola-Villalobos P; Donate-López J; Calvo-González C; Reche-Frutos J; Alejandre-Alba N; Díaz-Valle D
Acta Ophthalmol; 2008 Feb; 86(1):115-6. PubMed ID: 17680838
[No Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
Minnella AM; Savastano CM; Ziccardi L; Scupola A; Falsini B; Balestrazzi E
Acta Ophthalmol; 2008 Sep; 86(6):683-7. PubMed ID: 17995986
[TBL] [Abstract][Full Text] [Related]
11. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks.
Teixeira A; Moraes N; Farah ME; Bonomo PP
Acta Ophthalmol Scand; 2006 Dec; 84(6):835-6. PubMed ID: 17083556
[No Abstract] [Full Text] [Related]
12. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab.
Bakri SJ; Donaldson MJ; Link TP
Eye (Lond); 2006 Dec; 20(12):1474-5. PubMed ID: 16680105
[No Abstract] [Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
Fong KC; Barry C; McAllister IL
Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.
Shaikh S
Indian J Ophthalmol; 2008; 56(3):259. PubMed ID: 18417840
[No Abstract] [Full Text] [Related]
15. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits.
Ameri H; Chader GJ; Kim JG; Sadda SR; Rao NA; Humayun MS
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5708-15. PubMed ID: 18055823
[TBL] [Abstract][Full Text] [Related]
16. Pneumatic displacement and intravitreal bevacizumab in the management of subretinal haemorrhage caused by choroidal neovascularization.
Hasler PW; la Cour M; Villumsen J
Acta Ophthalmol Scand; 2007 Aug; 85(5):577-9. PubMed ID: 17559558
[No Abstract] [Full Text] [Related]
17. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
Avery RL
Retina; 2006 Mar; 26(3):352-4. PubMed ID: 16508438
[No Abstract] [Full Text] [Related]
18. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
Saito W; Kase S; Ohgami K; Mori S; Ohno S
Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
